Difference between revisions of "Bredesen Protocol"

From ApoE4.Info Wiki
Jump to: navigation, search
(Replaced tables of tests and ranges from 1st book with tests/values from Dr B's second book)
m (modified opening note to say we are in process of updating)
Line 1: Line 1:
<big>'''Note''' that with the publication of Dr Bredesen's 2nd book, '''''The End of Alzheimer's Program''''', published on August 18, 2020, some of the information in this Wiki, specifically with regard to biomarkers and their target values, may have been superseded.  An update is in the works, please bear with us as we work to update.</big>     
<big>'''Note''' that with the publication of Dr Bredesen's 2nd book, '''''The End of Alzheimer's Program''''', published on August 18, 2020, some of the information in this Wiki may have been superseded.  Updating this wiki is in the works, please bear with us as we update.</big>     

Revision as of 15:05, 20 August 2020


Note that with the publication of Dr Bredesen's 2nd book, The End of Alzheimer's Program, published on August 18, 2020, some of the information in this Wiki may have been superseded. Updating this wiki is in the works, please bear with us as we update.

Dr. Dale Bredesen has created the ReCODE protocol that involves multiple strategies to address specific health issues that contribute to Alzheimer's Disease (AD). The results of each strategy are measured by using blood tests, cognitive evaluations, and other markers of overall health improvements. Actions are tweaked over time to aim for optimal lab and evaluation results. His analogy is to think of AD as a leaky roof - there are as many as 36 leaks in the AD roof that need to be addressed to stop the problem. Not every patient will have the same leaks, and the protocol is customized based on the patient’s genetics, current health, and lifestyle.

In 2014, his first published paper on the protocol, Reversal of Cognitive Decline, highlighted 10 case studies. Of those 10 people, nine showed enough improvement to return to normal life activities. Several hundred people with cognitive impairment have since followed the protocol, and most have seen a reversal of cognitive impairment. He published results of reversing various levels of cognitive decline in Reversal of Cognitive Decline: 100 patients, published October 2018. His book The End of Alzheimer's, published August 2017 discusses his protocol and explains many of the mechanisms of Alzheimer's.

Bredesen’s protocol has not been tested as a preventative, however in a May 2019 podcast interview, Dr Bredesen did say that he’s never had someone at risk come in for prevention and develop even mild cognitive impairment. Research has shown that amyloid-β is deposited in E4 carriers as early as their thirties, so addressing components prior to experiencing cognitive impairment symptoms will likely lead to better health and cognition in aging. Members on the APOE4.Info forum who follow the protocol report improvements not only in health but also in cognition, even if they do not have an SCI or MCI diagnosis.

Although Bredesen does not see private patients, he has made his protocol available to those seeking doctor assistance through AHNP: Precision Health. MPI Cognition, his previous affiliation, was acquired by AHNP and his prior affiliation with Muses Labs has ended.

The following list links to summaries of why each strategy is important, what you can do, and a selection of research references.

Diet Strategies

Optimize diet

Enhance autophagy and ketogenesis

Improve GI Health

Lifestyle Strategies

Reduce stress

Optimize sleep


Rule out sleep apnea

Optimize mitochondrial function

Lab Tests to Track and Treat


B vitamins


Insulin sensitivity (insulin and blood glucose)


Zn:fCu ratio

Vitamin D

Rule out heavy metal toxicity

Optimize antioxidants  ??

Brain Strategies

Brain stimulation

Reduction of Aß

Cognitive enhancement

Increase NGF

Provide synaptic structural components

Increase focus

Increase SirT1 function

Inhalational Alzheimer's (editing note: update to types of AD)


Lab tests: Lab testing information

Supplements: Supplement ordering

Tracking results: Our member "optimize" made a Google spreadsheet using the recommended Cognoscopy test values in The End of Alzheimer's. This spreadsheet is a simple table to help you track your latest test results, with values flagged as "high", "low", or "in range". It's intended as a quick way to organize test results, and see at a glance where to make improvements.

The link to make your own copy of the spreadsheet for your private use is here: https://goo.gl/8t2dxi

Please note! The copied spreadsheet will let you type in the white areas, but this may cause errors in the formulas. If you accidentally type in a white area, hit "ctrl-Z" a few times to remove the typing, or download a fresh copy of the spreadsheet.

Summary of key tests for ReCode Protocol Taken from table 1 of Dr Bredesen's second book The End of Alzheimer's Program provided for quick reference, refer to the book for specific information. If you are following his first book, note that some of the biomarkers have changed.

Critical Tests Target Values Comments
Inflammation, protection, and vascular hs-CRP <0.9 mg/L Systemic Inflammation
Fasting insulin

Fasting Glucose
Hemoglobin A1c

3.0-5.0 μIU/mL*

70-90 mg/dL

Glycotoxicity and insulin resistance markers
*For those who are insulin sensitive, with fasting glucose <90 mg/dL, fasting insulin of < 3.0 is still a healthy range 
Body mass index (BMI) 18.5-25 Weight (lbs) x 703/height (inches)2
Waist to hip ratio (women)

Waist to hip ratio (man)



Homocysteine ≤7μmol/L Reflects methylation, inflammation, and detox
Vitamin B6

Vitamin B9(folate)
Vitamin B12

25-50 mcg/L (PP)

10-25 ng-mL
500-1500 pg/mL

Improve methylation and reduce homocysteine
Vitamin C

Vitamin D
Vitamin E

1.3-2.5 mg/dL

12-20 mg/L

Omega-6 to omega-3 ratio 1:1 to 4:1 (beware that <0.5:1 may be associated with bleeding tendency) Ratio of inflammatory to anti-inflammatory omega fats
Omega-3 index ≥10% (ApoE4+)

8-10% (ApoE4-)

Proportion of anti-inflammatory omega-3 fats
AA to EPA ratio (arachidonic acid to eicosapentaenoic acid ratio) <3:1 Ratio of inflammatory AA to anti-inflammatory EPA
A/G ratio (albumin to globulin ratio)



4.5-5.4 g/dL

Markers of inflammation, liver health, and amyloid clearance

Small dense LDL
Oxidized LDL


<28 mg/dL
<60 ng/mL

LDL-P is LDL particle number
Total cholesterol

HDL cholesterol
TG to HDL ratio

150-200 mg/dL

>50 mg/dL
<150 mg/dL

CoQ10 1.1-2.2 mcg/mL Affected by cholesterol level
Glutathione >250 mcg/mL (>814 μM) Major antioxidant and detoxicant
Leaky gut, leaky blood-brain barrier, gluten sensitivity, autoantibodies Negative
Minerals RBC-magnesium 5.2-6.5 mg/dL Preferable to serum magnesium
Copper 90-110 mcg/dL
Zinc 90-110 mcg/dL
Selenium 110-150-ng/mL
Potassium 4.5-5.5 mEq/L
Trophic Support Vitamin D 50-80 ng/mL (250H-D3)


50-250 pg/mL

1-20 ng/dL (P)

Women; age dependent

Cortisol (AM)
DHEA-S (women)
DHEA-S (men)

100-250 ng/dL

10-18 mcg/dL
100-380 mcg/dL
150-500 mcg/dL

Age dependent

Free Testosterone

500-1000 ng/dL

18-26 pg/ml

Men; age dependent
Free T3

Free T4
Reverse T3
Free T3 to reverse T3
Anti-thyroglobulin antibodies

3.2-4.2 pg/mL

1.3-1.8 ng/dL
<20 ng/dL
<2.0 mIU/L

Toxin-related Mercury


<5 mcg/L

<2 mcg/dL
<7 mcg/L
<2.5 mcg/dL

Heavy Metals
Mercury Tri-Test <50th percentile Hair, blood, urine
Organic toxins (urine) Negative Benzene, toluene, etc.
Glyphosate (urine) <1.0 mcg/g creatinine Herbicide
Copper to zinc ratio 0.8-1.2.1 Higher ratios associated with dementia


<2830 ng/mL

<2380 pg/mL
85-332 ng/mL
35-81 pg/mL

Associated with inflammatory response
Urinary mycotoxins Negative May include contributions from inhalation, ingestion, and infection


<20 mg/dL

<1.0 mg/dL

Reflects kidney function


<25 U/L

<25 U/L

Reflects liver damage
VCS (visual contrast sensitivity) Pass Failure associated with biotoxin exposure
ERMI test <2 Mold index from building
HERTSMI-2 test <11 Index of most toxic molds
Pathogen-related CD57 60-360 cells/μL Reduced with Lyme
MARCoNS Negative
Antibodies to tick-borne pathogens Negative Borrelia, Babesia, Bartonella, Ehrlichia, Anaplasma
Antibodies to Herpes family viruses Negative HSV-1, HSV-2, HHV-6, VZV, EBV, CMV
Neurophysiology Peak alpha frequency on quantitative EEG 8.9-11 Hz Slows with cognitive decline; useful for following progress
P300b on evoked response testing <450 ms Delayed with cognitive decline; useful for following progress
Other Tests MoCA (Montreal Cognitive Assessment) 28-30
Nocturnal oxygen saturation (SpO2) 96-98% Affected by living at high altitude
AHI (apnea-hypopnea index) <5 events per hour >5 indicates sleep apnea
Oral DNA Negative for pathogens P. gingivalis, T. denticola, etc.
Stool analysis No pathogens or dysbiosis
ImmuKnow (CD4 function, indicated by ATP production) ≥525 ng/mL Indicates function of helper cells of the cellular arm of adaptive immune system

Dr Bredesen's research


Dr Bredesen's book, The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline, published August 22, 2017. Amazon link to Dr Bredesen's book

Videos and interviews

  • He cites 6 types of Alzheimer's: (1) inflammatory (2) atrophic (1.5) glycotoxic (3) toxic (4) vascular and (5) traumatic. Vascular and traumatic are new since publication of his book
  • In his markers for glycotoxicity, he cites fasted insulin of 5.0 (his book cites 4.5) or lower and HbA1c 4.5 to 5.2 (the book cites less than 5.6)
  • Dr Bredesen said that the Big Four to avoid are: grains, simple carbs, dairy, and lectins. Pro-inflammatory lectins have been added since publication of his book.
  • He added another mold/mycotoxin to his list: Wallemia. The big 5 molds are now: Stachybotrys, Aspergillus, Penicillium, Chaetomium, and Wallemia.

Dr Bredesen's Papers

  • The first version of Dr Bredesen’s protocol (which is similar to the above) can be found in his paper: Reversal of cognitive decline: A novel therapeutic program, published September 2014, https://www.ncbi.nlm.nih.gov/pubmed/25324467

Subsequent papers of Dr Bredesen do not address his protocol, but further examine his findings. They include:

This paper addresses the common criticism that the original paper only covered a small number of patients. This paper documents improvement in cognition of 100 patients treated by several different physicians thus providing further support for a randomized, controlled clinical trial of the protocol and overall approach: